Multiple Myeloma Clinical Trial
— ARC-12Official title:
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Verified date | June 2024 |
Source | Arcus Biosciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Status | Active, not recruiting |
Enrollment | 94 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Male or female participants = 18 years of age (or age = regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent. - Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Adequate organ and marrow function Exclusion Criteria: - History of trauma or major surgery within 28 days prior to the first dose of study treatment. - Prior treatment with an anti-TIGIT antibody. - Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment. - Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment. - Discontinued prior immunotherapy for immune related adverse events with a high severity. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Poland | Specjalistyczna Praktyka Lekarska Slawomir Mandziuk | Lubin | |
Poland | Med-Polonia Sp. z o.o. | Poznan | |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | Clínica Universidad de Navarra | Madrid | |
Spain | Clínica Universidad de Navarra - Madrid | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | START MADRID Hospital Unviersitario Fundacion Jimenez Diaz | Madrid | |
Spain | START MADRID_Hospital Universitario HM Sanchinarro - CIOCC | Madrid | |
United States | Ohio State University | Columbus | Ohio |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | Goshen Health System | Goshen | Indiana |
United States | Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | Mayo Clinic Jacksonville - PPDS | Jacksonville | Florida |
United States | University of California, Los Angeles | Los Angeles | California |
United States | Norton Cancer Institute-Downtown | Louisville | Kentucky |
United States | University of Wisconsin - Madison | Madison | Wisconsin |
United States | Tennessee Onocology - Nashville | Nashville | Tennessee |
United States | Columbia University Medical Center | New York | New York |
United States | University of Oklahoma Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
United States | Mayo Clinic - PPDS | Rochester | Minnesota |
United States | START South Texas Accelerated Research Therapeutics - San Antonio | San Antonio | Texas |
United States | START South Texas Accelerated Research Therapeutics - Mountain Region | West Valley City | Utah |
Lead Sponsor | Collaborator |
---|---|
Arcus Biosciences, Inc. | Gilead Sciences |
United States, Poland, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of participants with Adverse Events | From first study treatment administration until up to 90 days after the last dose (Approximately 1 year) | ||
Primary | Percentage of participants who experience a Dose Limiting Toxicity | From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) or Day 42 (Q6W arm) | ||
Secondary | Serum concentration of AB308 | Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months) | ||
Secondary | Serum concentration of zimberelimab | Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months) | ||
Secondary | Percentage of participants with anti-drug antibodies to AB308 | Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months) | ||
Secondary | Percentage of participants with anti-drug antibodies to zimberelimab | Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months) | ||
Secondary | Percentage of participants with Objective Response | From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years) | ||
Secondary | Duration of Response | From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) | ||
Secondary | Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for >6 months | From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |